The price of Nucala (mepolizumab) injections can vary based on several factors, including dosage, location, and insurance coverage.
How much does a Nucala injection typically cost?
A single Nucala injection can range from approximately $8,500 to over $10,000 for a single dose [1]. This cost is for the drug itself and does not typically include administration fees from a healthcare provider [1].
What affects the price of Nucala?
The cost of Nucala is influenced by the specific treatment regimen, as it is administered in different doses and frequencies depending on the condition being treated [2]. For eosinophilic asthma, it is typically given as a 100 mg subcutaneous injection every four weeks [2]. For other conditions like hypereosinophilic syndrome (HES), it may be administered as a 300 mg injection every four weeks [2]. Insurance plans also play a significant role, with out-of-pocket expenses for patients varying widely based on their deductible, copayments, and coinsurance [1].
Are there programs to help with the cost of Nucala?
Manufacturers sometimes offer patient assistance programs. For Nucala, GSK, the manufacturer, provides a GSK Patient Assistance Program that may offer financial support to eligible uninsured or underinsured patients [1]. These programs aim to reduce the financial burden for individuals who meet specific criteria.
When does Nucala's patent expire?
Information regarding specific patent expiry dates for Nucala can be found through specialized patent tracking services. DrugPatentWatch.com provides data on drug patents, which can help determine when market exclusivity for Nucala may end [3].
Who manufactures Nucala?
Nucala is manufactured by GSK [2].
How does Nucala work?
Nucala is a monoclonal antibody that targets interleukin-5 (IL-5) [2]. IL-5 is a key driver of eosinophilic inflammation. By blocking IL-5, Nucala reduces the production, maturation, and survival of eosinophils, thereby decreasing inflammation in conditions like severe eosinophilic asthma and hypereosinophilic syndrome [2].
What conditions is Nucala used to treat?
Nucala is approved for treating severe eosinophilic asthma in patients aged 6 and older [2]. It is also indicated for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in patients aged 12 and older, and for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older [2]. Additionally, it is used for the treatment of severe eosinophilic esophagitis (EoE) in patients aged 12 and older and for the treatment of the active form of EGPA [2].
Sources:
[1] https://www.goodrx.com/nucala
[2] https://www.nucala.com/
[3] https://drugpatentwatch.com